Radiology, Vol 186, 855-860, Copyright © 1993 by Radiological Society of North America

ARTICLES

Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients

J Haustein, M Laniado, HP Niendorf, T Louton, W Beck, J Planitzer, M Schoffel, M Reiser, W Kaiser and W Schorner
Department of Clinical Research Diagnostics, Schering AG, Berlin, Germany.

To investigate the safety, patient tolerance, and efficacy with 0.3 mmol/kg gadopentetate dimeglumine in magnetic resonance (MR) imaging of the central nervous system (CNS), a phase 3 trial was conducted in 199 patients with suspected CNS lesions. Patients received either 0.1 or 0.3 mmol/kg gadopentate dimeglumine (injection time, 15 seconds and 45 seconds, respectively). T1- and T2-weighted spin-echo sequences were performed at either 0.5 T or 1.5 T. In 80 patients with enhancing brain lesions, contrast-to-noise ratios (C/Ns) were calculated, and lesion-to- brain contrast was evaluated visually. Six patients (6%) in each dose group reported adverse events. Eight adverse events occurred with 0.1 mmol/kg and seven with 0.3 mmol/kg. Vital signs and laboratory values did not change significantly. C/N (P < .05) and visual assessment ratings were higher with 0.3 mmol/kg than with 0.1 mmol/kg. According to these preliminary results, 0.3 mmol/kg gadopentetate dimeglumine is safe and well tolerated when administered at approximately 1 mL/sec.

This article has been cited by other articles:

				C. U. Herborn, V. M. Runge, D. M. Watkins, J. M. Gendron, and L. G. Naul MR Angiography of the Renal Arteries: Intraindividual Comparison of Double-Dose Contrast Enhancement at 1.5 T with Standard Dose at 3 T Am. J. Roentgenol., January 1, 2008; 190(1): 173 - 177. [Abstract] [Full Text] [PDF]

				K. R. Maravilla, J. A. Maldjian, I. M. Schmalfuss, M. J. Kuhn, B. C. Bowen, F. J. Wippold II, V. M. Runge, M. V. Knopp, S. Kremer, L. J. Wolansky, et al. Contrast Enhancement of Central Nervous System Lesions: Multicenter Intraindividual Crossover Comparative Study of Two MR Contrast Agents Radiology, August 1, 2006; 240(2): 389 - 400. [Abstract] [Full Text] [PDF]

				C. Krautmacher, W. A. Willinek, H. J. Tschampa, M. Born, F. Traber, J. Gieseke, H. J. Textor, H. H. Schild, and C. K. Kuhl Brain Tumors: Full- and Half-Dose Contrast-enhanced MR Imaging at 3.0 T Compared with 1.5 T--Initial Experience Radiology, December 1, 2005; 237(3): 1014 - 1019. [Abstract] [Full Text] [PDF]

				M. V. Knopp, V. M. Runge, M. Essig, M. Hartman, O. Jansen, M. A. Kirchin, A. Moeller, A. H. Seeberg, and K.-P. Lodemann Primary and Secondary Brain Tumors at MR Imaging: Bicentric Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine Radiology, January 1, 2004; 230(1): 55 - 64. [Abstract] [Full Text] [PDF]

				K. Bhirangi, M. Gilfeather, E. S. Siegelman, M. D. Schnall, G. A. Holland, J. P. Carpenter, and M. A. Golden Comparison of Preoperative Three-Dimensional Gadolinium-Enhanced Magnetic Resonance Imaging to the Operative Assessment of Abdominal Aortic Aneurysm Anatomy: A Retrospective Study Vascular and Endovascular Surgery, March 1, 2000; 34(2): 107 - 113. [Abstract] [PDF]

				J. Breslau, J. G. Jarvik, D. R. Haynor, W. T. Longstreth Jr, D. L. Kent, and K. R. Maravilla MR Contrast Media in Neuroimaging: A Critical Review of the Literature AJNR Am. J. Neuroradiol., April 1, 1999; 20(4): 670 - 675. [Abstract] [Full Text]